Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UniversitatSpital USZ, Zurich, Switzerland
Contact: Study coordinator (Tobias Weiss, MD)

Study leads

Tobias Weiss, PhD, MD
Principal Investigator
Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Astrocytoma, Grade III

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chicago, United States · New York, United States

Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients

Glioblastoma Multiforme

Abroad (travel likely)RecruitingPHASE2

Calgary, Canada · Edmonton, Canada

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

Glioblastoma Multiforme · Glioblastoma Multiforme, Adult · Supratentorial Glioblastoma

Abroad (travel likely)RecruitingPHASE2

Cleveland, United States

Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas

Glioblastoma, Recurrent · Lower Grade Glioma, Recurrent

Abroad (travel likely)RecruitingPHASE2

Beijing, China